Evidence map›Paper›PMID 38315789›Full record

ArticleCancer research2024

Integrating AI-Powered Digital Pathology and Imaging Mass Cytometry Identifies Key Classifiers of Tumor Cells, Stroma, and Immune Cells in Non-Small Cell Lung Cancer.

Alessandra Rigamonti, Marika Viatore, Rebecca Polidori, Daoud Rahal, Marco Erreni, Maria Rita Fumagalli, Damiano Zanini, Andrea Doni, Anna Rita Putignano, Paola Bossi and 11 more

Open access · hybridAbstract read
In one paragraph

Article in Cancer research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed
5.9field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 21 citations in OpenAlex.

  1. Trial
  2. Review
  3. Article
  4. Article
  5. Review
  6. Review
  7. Review
  8. Review
  9. Review
  10. Review
  11. Review
  12. Article
  13. Terminally exhausted CD8Frontiers in immunology · 2025
    Review
  14. Review
  15. Article
  16. Review
  17. Article
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors at 5 institutions in 4 countries.

Alessandra Rigamonti *Department of Immunology and Inflammation, IRCCS Humanitas Research Hospital; Rozzano (Milan), Italy.ORCID 0000-0002-1938-2278
Marika Viatore *Department of Immunology and Inflammation, IRCCS Humanitas Research Hospital; Rozzano (Milan), Italy.ORCID 0000-0001-9554-6468
Rebecca Polidori *Department of Immunology and Inflammation, IRCCS Humanitas Research Hospital; Rozzano (Milan), Italy.ORCID 0000-0003-3016-7613
Daoud RahalDepartment of Pathology, IRCCS Humanitas Research Hospital; Rozzano (Milan), Italy.ORCID 0000-0002-5579-7550
Marco ErreniUnit of Advanced Optical Microscopy, IRCCS Humanitas Research Hospital, Rozzano, Milan, Italy.ORCID 0000-0002-1922-0818
Maria Rita FumagalliUnit of Advanced Optical Microscopy, IRCCS Humanitas Research Hospital, Rozzano, Milan, Italy.ORCID 0000-0003-3404-5779
Damiano ZaniniUnit of Advanced Optical Microscopy, IRCCS Humanitas Research Hospital, Rozzano, Milan, Italy.ORCID 0000-0002-7156-2225
Andrea DoniUnit of Advanced Optical Microscopy, IRCCS Humanitas Research Hospital, Rozzano, Milan, Italy.ORCID 0000-0001-9203-5814
Anna Rita PutignanoDepartment of Immunology and Inflammation, IRCCS Humanitas Research Hospital; Rozzano (Milan), Italy.ORCID 0000-0002-6462-9188
Paola BossiDepartment of Pathology, IRCCS Humanitas Research Hospital; Rozzano (Milan), Italy.ORCID 0000-0003-2024-6668
Emanuele VoulazDepartment of Biomedical Science, Humanitas University, Pieve Emanuele, Milan, Italy.ORCID 0000-0002-9091-6797
Marco AlloisioDivision of Thoracic Surgery, IRCCS Humanitas Research Hospital, Rozzano (Milan), Italy.ORCID 0000-0002-1415-5439
Sabrina RossiMedical Oncology and Hematology Unit, IRCCS Humanitas Research Hospital, Rozzano (Milan), Italy.ORCID 0000-0001-8853-0775
Paolo Andrea ZucaliDepartment of Biomedical Science, Humanitas University, Pieve Emanuele, Milan, Italy.ORCID 0000-0002-2274-1702
Armando SantoroDepartment of Biomedical Science, Humanitas University, Pieve Emanuele, Milan, Italy.ORCID 0000-0003-1709-9492
Vittoria BalzanoImmunology and Immunotherapy Unit, IRCCS Regina Elena National Cancer Institute, Rome, Italy.ORCID 0009-0003-2613-1519
Paola NisticòImmunology and Immunotherapy Unit, IRCCS Regina Elena National Cancer Institute, Rome, Italy.ORCID 0000-0003-4409-2261
Friedrich FeuerhakeInstitute for Neuropathology, University Clinic Freiburg, Freiburg, Germany.ORCID 0000-0002-1234-982X
Alberto MantovaniDepartment of Immunology and Inflammation, IRCCS Humanitas Research Hospital; Rozzano (Milan), Italy.ORCID 0000-0001-5578-236X
Massimo LocatiDepartment of Immunology and Inflammation, IRCCS Humanitas Research Hospital; Rozzano (Milan), Italy.ORCID 0000-0003-3077-590X
Federica MarchesiDepartment of Immunology and Inflammation, IRCCS Humanitas Research Hospital; Rozzano (Milan), Italy.ORCID 0000-0002-7212-5721
IRCCS Humanitas Research Hospital · ITHumanitas University · ITUniversity of Milan · ITNational Cancer Institute · MYUniversity of Freiburg · DE

Funding

Associazione italiana per la ricerca sul cancro (AIRC) AIRC IG 2020 - ID. 24393Ministero della Salute (Italy Ministry of Health) RF-2019-12369142Ministero della salute-progetti di rete ACC RCR-2020-23670066
6 · The paper itself

Abstract

Artificial intelligence (AI)-powered approaches are becoming increasingly used as histopathologic tools to extract subvisual features and improve diagnostic workflows. On the other hand, hi-plex approaches are widely adopted to analyze the immune ecosystem in tumor specimens. Here, we aimed at combining AI-aided histopathology and imaging mass cytometry (IMC) to analyze the ecosystem of non-small cell lung cancer (NSCLC). An AI-based approach was used on hematoxylin and eosin (H&E) sections from 158 NSCLC specimens to accurately identify tumor cells, both adenocarcinoma and squamous carcinoma cells, and to generate a classifier of tumor cell spatial clustering. Consecutive tissue sections were stained with metal-labeled antibodies and processed through the IMC workflow, allowing quantitative detection of 24 markers related to tumor cells, tissue architecture, CD45+ myeloid and lymphoid cells, and immune activation. IMC identified 11 macrophage clusters that mainly localized in the stroma, except for S100A8+ cells, which infiltrated tumor nests. T cells were preferentially localized in peritumor areas or in tumor nests, the latter being associated with better prognosis, and they were more abundant in highly clustered tumors. Integrated tumor and immune classifiers were validated as prognostic on whole slides. In conclusion, integration of AI-powered H&E and multiparametric IMC allows investigation of spatial patterns and reveals tissue relevant features with clinical relevance. SIGNIFICANCE: Leveraging artificial intelligence-powered H&E analysis integrated with hi-plex imaging mass cytometry provides insights into the tumor ecosystem and can translate tumor features into classifiers to predict prognosis, genotype, and therapy response.

Indexed as

Carcinoma, Non-Small-Cell LungLung NeoplasmsArtificial IntelligenceEcosystemHumansImage Cytometry

Identifiers

PMID38315789
PMCPMC10982643
OpenAlexW4391529234

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.